Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Felix, Joana ^a,b   Lambert, Jérome ^b,c,d   Roelens, Marie ^a   Maubec, Eve ^e   Guermouche, Hélène ^a   Pages, Cécile ^c   Sidina, Irina ^c   Cordeiro, Debora J ^a,b,c   Maki, Guitta ^c   Chasset, François ^c   Porcher, Raphaël ^b,d,f   Bagot, Martine ^b,c   Caignard, Anne ^a   Toubert, Antoine ^a,b,c   Lebbé, Céleste ^b,c   Moins Teisserenc, Hélène ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d PARIS DESCARTES UNIVERSITY   (France)

^e BICHAT HOSPITAL   (France)

^f HÔTEL DIEU   (France)

Author keywords

CTLA 4; immunotherapy; ipilimumab; melanoma; memory T cells; TSCM

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANZYME B; IPILIMUMAB; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE CONTROL; DRUG SAFETY; ENTEROCOLITIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEPATITIS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MEMORY T LYMPHOCYTE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; RASH; TREATMENT RESPONSE; UPREGULATION;

EID: 84978117047     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1136045     Document Type: Article

References (56)

1. C.Garbe, T.K.Eigentler, U.Keilholz, A.Hauschild, J.M.Kirkwood. Systematic review of medical treatment in melanoma:current status and future prospects. Oncologist 2011; 16:5-24; PMID:21212434; http://dx.doi.org/10.1634/theoncologist.2010-0190
2. C.M.Balch, J.E.Gershenwald, S.J.Soong, J.F.Thompson, M.B.Atkins, D.R.Byrd, A.C.Buzaid, A.J.Cochran, D.G.Coit, S.Ding et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol:Off J Am Soc Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
3. M.T.Lotze, S.A.Rosenberg. The immunologic treatment of cancer. CA:Cancer J Clin 1988; 38:68-94; PMID:2450624; http://dx.doi.org/10.3322/canjclin.38.2.68
4. S.A.Rosenberg, B.S.Packard, P.M.Aebersold, D.Solomon, S.L.Topalian, S.T.Toy, P.Simon, M.T.Lotze, J.C.Yang, C.A.Seipp et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 1988; 319:1676-80; PMID:3264384; http://dx.doi.org/10.1056/NEJM198812223192527
5. S.Lee, K.Margolin. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep 2012; 14:468-74; PMID:22878966; http://dx.doi.org/10.1007/s11912-012-0257-5
6. J.B.Haanen. Immunotherapy of melanoma. EJC Suppl 2013; 11:97-105; PMID:26217118; http://dx.doi.org/10.1016/j.ejcsup.2013.07.013
7. R.J.Greenwald, G.J.Freeman, A.H.Sharpe. The B7 family revisited. Annu Rev Immunol 2005; 23:515-48; PMID:15771580; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115611
8. B.Salomon, J.A.Bluestone. Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19:225-52; PMID:11244036; http://dx.doi.org/10.1146/annurev.immunol.19.1.225
9. T.L.Walunas, D.J.Lenschow, C.Y.Bakker, P.S.Linsley, G.J.Freeman, J.M.Green, C.B.Thompson, J.A.Bluestone. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; http://dx.doi.org/10.1016/1074-7613(94)90071-X
10. D.R.Leach, M.F.Krummel, J.P.Allison. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, NY) 1996; 271:1734-6; PMID:8596936; http://dx.doi.org/10.1126/science.271.5256.1734
11. C.B.Thompson, J.P.Allison. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7:445-50; PMID:9354465; http://dx.doi.org/10.1016/S1074-7613(00)80366-0
12. G.Q.Phan, J.C.Yang, R.M.Sherry, P.Hwu, S.L.Topalian, D.J.Schwartzentruber, N.P.Restifo, L.R.Haworth, C.A.Seipp, L.J.Freezer et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proce Natl Acad Sci U S A 2003; 100:8372-7; PMID:12826605; http://dx.doi.org/10.1073/pnas.1533209100
13. F.S.Hodi, M.C.Mihm, R.J.Soiffer, F.G.Haluska, M.Butler, M.V.Seiden, T.Davis, R.Henry-Spires, S.MacRae, A.Willman et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100:4712-7; PMID:12682289; http://dx.doi.org/10.1073/pnas.0830997100
14. A.M.Lesokhin, M.K.Callahan, M.A.Postow, J.D.Wolchok. On being less tolerant:Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 2015; 7:280sr1; PMID:25810313; http://dx.doi.org/10.1126/scitranslmed.3010274
15. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
16. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, D.MDJ, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
17. D.McDermott, C.Lebbe, F.S.Hodi, M.Maio, J.S.Weber, J.D.Wolchok, J.A.Thompson, C.M.Balch. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Rev 2014; 40:1056-64; PMID:25060490; http://dx.doi.org/10.1016/j.ctrv.2014.06.012
18. D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol:Off J Am Soc Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
19. S.G.Downey, J.A.Klapper, F.O.Smith, J.C.Yang, R.M.Sherry, R.E.Royal, U.S.Kammula, M.S.Hughes, T.E.Allen, C.L.Levy et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res:Off J Am Assoc Cancer Res 2007; 13:6681-8; PMID:17982122; http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
20. Y.C.Kong, W.Z.Wei, Y.Tomer. Opportunistic autoimmune disorders:from immunotherapy to immune dysregulation. Ann New York Acad Sci 2010; 1183:222-36; PMID:20146718; http://dx.doi.org/10.1111/j.1749-6632.2009.05138.x
21. G.Y.Ku, J.Yuan, D.B.Page, S.E.Schroeder, K.S.Panageas, R.D.Carvajal, P.B.Chapman, G.K.Schwartz, J.P.Allison, J.D.Wolchok. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting:lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-75; PMID:20143434; http://dx.doi.org/10.1002/cncr.24951
22. A.M.Di Giacomo, R.Danielli, L.Calabro, E.Bertocci, C.Nannicini, D.Giannarelli, A.Balestrazzi, F.Vigni, V.Riversi, C.Miracco et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol, Immunother:CII 2011; 60:467-77; PMID:21170646; http://dx.doi.org/10.1007/s00262-010-0958-2
23. J.Delyon, C.Mateus, D.Lefeuvre, E.Lanoy, L.Zitvogel, N.Chaput, S.Roy, A.M.Eggermont, E.Routier, C.Robert. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma:an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol:Off J Euro Soc Med Oncol / ESMO 2013; 24:1697-703; PMID:23439861; http://dx.doi.org/10.1093/annonc/mdt027
24. F.Chasset, C.Pages, L.Biard, J.Roux, I.Sidina, I.Madelaine, N.Basset-Seguin, M.Viguier, N.Madjlessi-EzrA, P.Schneider et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma:negative impact of baseline corticosteroids. Eur J Dermatol 2015; 25:36-44; PMID:25500362; http://dx.doi.org/10.1684/ejd.2014.2471
25. B.Comin-Anduix, Y.Lee, J.Jalil, A.Algazi, P.de la Rocha, L.H.Camacho, V.A.Bozon, C.A.Bulanhagui, E.Seja, A.Villanueva et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Trans Med 2008; 6:22; PMID:18452610; http://dx.doi.org/10.1186/1479-5876-6-22
26. D.Ng Tang, Y.Shen, J.Sun, S.Wen, J.D.Wolchok, J.Yuan, J.P.Allison, P.Sharma. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013; 1:229-34; PMID:24777852; http://dx.doi.org/10.1158/2326-6066.CIR-13-0020
27. J.J.Luke, P.A.Ott. PD-1 pathway inhibitors:the next generation of immunotherapy for advanced melanoma. Oncotarget 2015; 6:3479-92; PMID:25682878; http://dx.doi.org/10.18632/oncotarget.2980
28. M.A.Postow, J.Chesney, A.C.Pavlick, C.Robert, K.Grossmann, D.McDermott, G.P.Linette, N.Meyer, J.K.Giguere, S.S.Agarwala et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New Engl J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
29. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
30. A.Hutloff, A.M.Dittrich, K.C.Beier, B.Eljaschewitsch, R.Kraft, I.Anagnostopoulos, R.A.Kroczek. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-6; PMID:9930702; http://dx.doi.org/10.1038/16717
31. Y.Burmeister, T.Lischke, A.C.Dahler, H.W.Mages, K.P.Lam, A.J.Coyle, R.A.Kroczek, A.Hutloff. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol 2008; 180:774-82; PMID:18178815; http://dx.doi.org/10.4049/jimmunol.180.2.774
32. A.M.Intlekofer, N.Takemoto, E.J.Wherry, S.A.Longworth, J.T.Northrup, V.R.Palanivel, A.C.Mullen, C.R.Gasink, S.M.Kaech, J.D.Miller et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005; 6:1236-44; PMID:16273099; http://dx.doi.org/10.1038/ni1268
33. R.D.Fritsch, X.Shen, G.P.Sims, K.S.Hathcock, R.J.Hodes, P.E.Lipsky. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005; 175:6489-97; PMID:16272303; http://dx.doi.org/10.4049/jimmunol.175.10.6489
34. L.Gattinoni, E.Lugli, Y.Ji, Z.Pos, C.M.Paulos, M.F.Quigley, J.R.Almeida, E.Gostick, Z.Yu, C.Carpenito et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446
35. T.Scholzen, J.Gerdes. The Ki-67 protein:from the known and the unknown. J Cell Physiol 2000; 182:311-22; PMID:10653597; http://dx.doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
36. T.L.Whiteside. Immune responses to cancer:are they potential biomarkers of prognosis? Front Oncol 2013; 3:107; PMID:23730621; http://dx.doi.org/10.3389/fonc.2013.00107
37. G.Mignot, A.Hervieu, P.Vabres, S.Dalac, G.Jeudy, B.Bel, L.Apetoh, F.Ghiringhelli. Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients. PloS One 2014; 9:e105907; PMID:25170840; http://dx.doi.org/10.1371/journal.pone.0105907
38. E.Simeone, G.Gentilcore, D.Giannarelli, A.M.Grimaldi, C.Caraco, M.Curvietto, A.Esposito, M.Paone, M.Palla, E.Cavalcanti et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol, Immunother:CII 2014; 63:675-83; PMID:24695951; http://dx.doi.org/10.1007/s00262-014-1545-8
39. M.K.Callahan, J.D.Wolchok, J.P.Allison. Anti-CTLA-4 antibody therapy:immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37:473-84; PMID:21074063; http://dx.doi.org/10.1053/j.seminoncol.2010.09.001
40. C.I.Liakou, A.Kamat, D.N.Tang, H.Chen, J.Sun, P.Troncoso, C.Logothetis, P.Sharma. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105:14987-92; PMID:18818309; http://dx.doi.org/10.1073/pnas.0806075105
41. B.C.Carthon, J.D.Wolchok, J.Yuan, A.Kamat, D.S.Ng Tang, J.Sun, G.Ku, P.Troncoso, C.J.Logothetis, J.P.Allison et al. Preoperative CTLA-4 blockade:tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res:Off J Am Assoc Cancer Res 2010; 16:2861-71; PMID:20460488; http://dx.doi.org/10.1158/1078-0432.CCR-10-0569
42. A.Zlotnik, O.Yoshie. The chemokine superfamily revisited. Immunity 2012; 36:705-16; PMID:22633458; http://dx.doi.org/10.1016/j.immuni.2012.05.008
43. T.Duhen, R.Geiger, D.Jarrossay, A.Lanzavecchia, F.Sallusto. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10:857-63; PMID:19578369; http://dx.doi.org/10.1038/ni.1767
44. J.R.Groom, A.D.Luster. CXCR3 in T cell function. Exp Cell Res 2011; 317:620-31; PMID:21376175; http://dx.doi.org/10.1016/j.yexcr.2010.12.017
45. A.V.Gorbachev, H.Kobayashi, D.Kudo, C.S.Tannenbaum, J.H.Finke, S.Shu, J.M.Farber, R.L.Fairchild. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol 2007; 178:2278-86; PMID:17277133; http://dx.doi.org/10.4049/jimmunol.178.4.2278
46. I.M.Mullins, C.L.Slingluff, J.K.Lee, C.F.Garbee, J.Shu, S.G.Anderson, M.E.Mayer, W.A.Knaus, D.W.Mullins. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64:7697-701; PMID:15520172; http://dx.doi.org/10.1158/0008-5472.CAN-04-2059
47. A.Ribas, B.Comin-Anduix, J.S.Economou, T.R.Donahue, P.de la Rocha, L.F.Morris, J.Jalil, V.B.Dissette, I.P.Shintaku, J.A.Glaspy et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res:Off J Am Assoc Cancer Res 2009; 15:390-9; PMID:19118070; http://dx.doi.org/10.1158/1078-0432.CCR-08-0783
48. R.R.Huang, J.Jalil, J.S.Economou, B.Chmielowski, R.C.Koya, S.Mok, H.Sazegar, E.Seja, A.Villanueva, J.Gomez-Navarro et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res:Off J Am Assoc Cancer Res 2011; 17:4101-9; PMID:21558401; http://dx.doi.org/10.1158/1078-0432.CCR-11-0407
49. Y.D.Mahnke, T.M.Brodie, F.Sallusto, M.Roederer, E.Lugli. The who's who of T-cell differentiation:human memory T-cell subsets. Euro J Immunol 2013; 43:2797-809; PMID:24258910; http://dx.doi.org/10.1002/eji.201343751
50. R.Das, R.Verma, M.Sznol, C.S.Boddupalli, S.N.Gettinger, H.Kluger, M.Callahan, J.D.Wolchok, R.Halaban, M.V.Dhodapkar et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194:950-9; PMID:25539810; http://dx.doi.org/10.4049/jimmunol.1401686
51. S.M.Kaech, W.Cui. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012; 12:749-61; PMID:23080391; http://dx.doi.org/10.1038/nri3307
52. E.L.Pearce, A.C.Mullen, G.A.Martins, C.M.Krawczyk, A.S.Hutchins, V.P.Zediak, M.Banica, C.B.DiCioccio, D.A.Gross, C.A.Mao et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (New York, NY) 2003; 302:1041-3; PMID:14605368; http://dx.doi.org/10.1126/science.1090148
53. G.M.Lord, R.M.Rao, H.Choe, B.M.Sullivan, A.H.Lichtman, F.W.Luscinskas, L.H.Glimcher. T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood 2005; 106:3432-9; PMID:16014561; http://dx.doi.org/10.1182/blood-2005-04-1393
54. Y.Zhu, S.Ju, E.Chen, S.Dai, C.Li, P.Morel, L.Liu, X.Zhang, B.Lu. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol 2010; 185:3174-83; PMID:20713880; http://dx.doi.org/10.4049/jimmunol.1000749
55. J.K.Hegel, K.Knieke, P.Kolar, S.L.Reiner, M.C.Brunner-Weinzierl. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Euro J Immunol 2009; 39:883-93; PMID:19224637; http://dx.doi.org/10.1002/eji.200838770
56. G.Li, Q.Yang, Y.Zhu, H.R.Wang, X.Chen, X.Zhang, B.Lu. T-Bet and eomes regulate the balance between the effector/central memory T cells versus memory stem like T cells. PloS One 2013; 8:e67401; PMID:23826287; http://dx.doi.org/10.1371/journal.pone.0067401